DCM
AKCA

Delpha Capital Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Delpha Capital Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,521
Closed -$26K – 1508
2017
Q4 		$26K Buy
+1,521
New +$29.8K 0.03% 644

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Delpha Capital Management's AKCA Position: Q1 2018 in Review

Delpha Capital Management sold out of Akcea Therapeutics Inc (AKCA) in Q1 2018, closing a stake of 1,521 shares — an estimated $26K sold.

Delpha Capital Management first reported a position in AKCA in Q4 2017 and held it in 1 quarter. The position peaked at $26K in Q4 2017. 57 funds tracked by Wall St. Rank hold AKCA as of Q1 2018.

  • Delpha Capital Management reported no remaining Akcea Therapeutics Inc position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 1,521 Akcea Therapeutics Inc shares in Q1 2018, an estimated $26K.
  • Delpha Capital Management first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Akcea Therapeutics Inc position peaked at $26K in Q4 2017.
  • 57 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.